

# Atopic Dermatitis Emergency Department, Urgent Care &

**Outpatient** 

### Center for Clinical Excellence

#### **Inclusion Criteria:**

Patients ≥ 2 months with essential features of atopic dermatitis

- Eczema (acute, subacute, chronic) with typical morphology and specific patterns:

Facial, neck and extensor involvement in infants and children Current or previous flexural lesions in any age group Sparing of the groin and axillary regions

Chronic or relapsing history

### **Exclusion Criteria:**

- Infants <2 months of age
- Known immunodeficiency
- Oncologic diagnosis

**Clinical Features by Age** 

**Diagnostic Features** 

**Differential Diagnosis** 

### **Atopic Dermatitis Flare?**

(signs and symptoms despite adherence to general treatment)

> Yes ¥

### **General Treatment**

### **Determine Severity and Impact on Quality of Life**

#### Mild

- Few patches of scaly pink to red
- Intermittent itching
- Little impact on daily activities

#### Moderate

- Multiple patches of scaly pink to red skin
- Frequent itching
- Excoriation or localized areas of thickened skin may be present
- Some impact on daily activities and sleep

#### Severe

- Widespread scaly skin
- Incessant itching
- Open, cracked areas of skin
- Lichenified skin
- Bleeding, oozing
- Significant impact on sleep, daily activities or mood

Treatment of flares should be started as soon as signs and symptoms appear

- Treat flares based on severity
- Adjunctive therapies
- Evaluate for Infections
- Treat infections
- Identify & treat co-existing conditions

Continue treatment for as long as symptoms persist and for 48 hours after symptoms resolve.

Continue General Treatment

Subspecialty Referral

**Allergy Introduction** 

CPP-ED-OP-UC Atopic Dermatitis Clinical Pathway Published: 1/4/2023; Last Revised: 1/4/2023

### **Diagnostic Features**

**Atopic dermatitis (also known as eczema)** is a condition characterized by dry, itchy and inflamed skin that tends to flare. It develops in early childhood and affects 10-20% of all children.

### **Typical Presentation:**

- Skin is typically itchy
- Depending on the body part(s) affected, the skin may be scaly, excoriated and thickened
- Lichenification, hypo/hyperpigmentation or skin superinfection

### **Associated features:**

- Keratosis pilaris, pityriasis alba, hyperlinear palms, ichthyosis
- Periocular changes
- Perioral changes, periauricular lesions or Dennie-Morgan lines
- Perifollicular accentuation, lichenification, prurigo-like lesions

### Diagnostic Criteria 1 or more of the following:

- Chronic or relapsing history
- Early age of onset, ≥2 months
- Personal and/or family history of atopy, IGE reactivity
- Facial, neck, and extensor involvement
- Current or previous flexural lesions in any age group
- Sparing of the groin and axillary regions

### Consider **Differential Diagnosis** when:

- Later onset
- Well defined borders
- · Symmetric distribution of rash
- Palms/soles, groin, axillae involvement
- Pink/salmon patches
- Alopecia or diarrhea
- Older child with no history of eczema

# Clinical Features by Age

### Infants:

- Begins at 2-3 months of age
- Involves scalp, face, trunk and extremities
- Diaper area spared
- Pruritic
- May contribute to disturbed sleep

### **Toddlers and Children:**

Rash locations:

Creases (elbows, knees, neck)

**Ankles** 

Wrists

- Hypo/hyperpigmentation
- Lichenification of skin (thickening due to scratching)
- Impaired skin barrier

Superinfection

Molluscum contagiosum

Warts

In patients < 2 months severe atopic dermatitis, failure to thrive or multiple infections may be related to immunodeficiency, metabolic disorders, or nutritional deficiencies.

Predominant diaper or perioral involvement may suggest nutritional deficiency.

Consider referral to allergy, dermatology or immunology

### **Differential Diagnosis**

### Seborrheic dermatitis

Scaly skin on scalp and eyebrows

May overlap with atopic dermatitis leading to more moderate atopic dermatitis

### Irritant/contact dermatitis

Older child with no history of eczema

Symmetric distribution of rash

Regional

Sudden onset

### Ringworm

Later onset

Multiple lesions

Annular, well defined lesions

Dorsal hands/feet

**Expanding border** 

Does not wax and wane

### Scabies

Prefers palms/soles, groin, axillae

### Psoriasis

Pink/salmon patches

Occipital scalp, elbows/knees/umbilicus, gluteal cleft, fingernails

Well defined borders

Infants with severe diaper rash

### Nutritional deficiency

Diaper area, perioral

**Dietary limitations** 

Other chronic health conditions

Diarrhea

Alopecia

Failing to respond to therapy

### **General Treatment**

### Optimal management includes:

- Identification of triggers
- Elimination of exacerbating factors
- . Restoration of the skin barrier function and hydration of the skin
- Treatment of skin inflammation

**Exacerbating factors** that further disrupt the epidermal barrier include excessive bathing <u>without</u> subsequent moisturization, low humidity environments, emotional distress, dry skin, overheating of skin and exposure detergents. Anything that causes pruritis should be avoided.

#### Additional recommendations:

Daily Bath for 5-10 minutes (to add moisture to skin and remove potential irritants from skin)

Use gentle, fragrance-free soap

Avoid bubble bath

General use of washcloths, sponges, loofas and baby wipes are not recommended

Pat dry skin after bath, leaving some moisture present

Apply generous amount of moisturizer immediately after bath

If using a steroid, use steroid before moisturizer

• Frequent use of emollients (to improve barrier function)

Twice daily apply cream or ointment (not lotion)

Apply within 3 minutes of bathing while skin still damp

Note: apply topical steroid medication 30-60 minutes before emollient

### Avoiding irritants

Irritants including dyes, perfumes, fragrances, botanical contact (cut grass, essential oils), and acidic foods touching the skin

Consider cotton clothing instead of wool, nylon

Use mild detergents without fragrance

Avoid fabric softeners

#### Treatment of irritation:

Diphenhydramine or hydroxyzine as needed before bed can prevent itching and scratching while asleep

### Diphenhydramine:

1 mg/kg/dose every 6 hours as needed

Usual dose children 12.5-25 mg/dose, adolescents 25-50 mg (max 50 mg/dose)

### Hydroxyzine:

Patient weight ≤40 kg: Oral: 2 mg/kg/day divided every 6 to 8 hours (max dose 25 mg/dose)

Patient weight >40 kg: Oral: 25 to 50 mg once daily at bedtime or twice daily

Children <6 years: Oral: 12.5 mg 3 to 4 times daily

Children ≥6 years and Adolescents: Oral: 12.5 to 25 mg 3 to 4 times daily

### **Treatment of Flares**

Treatment of flares should be started as soon as signs and symptoms appear and continued for >48 hours after symptoms subside

**Topical Steroids** (All covered by Ohio Medicaid)

- Use topical steroids on affected areas twice a day. Only use on affected areas of skin.
- Please use topical steroids as long as needed to treat eczema flare.
- If patient does not respond after 4-6 weeks of topical steroids, consider referral to dermatology.

Steroid-free options work best for mild eczema and / or areas of thinner skin

<u>Oral steroids</u> for severe head-toe disease that is too extensive for adequate coverage by topical steroids (not to be used more than once/year)

**Systemic therapy** should be considered based on severity, chronicity, quality of life, and coexistence of other atopic diseases (asthma, allergic rhinitis)

Adjuvant therapy options for pruritis, disordered sleep and frequent infections

See Appendix for additional guidance on approved body parts per topical steroid class.

Severity	Topical Steroid (covered by Ohio Medicaid)	Potency/Class	Approved Body Parts
Mild Atopic Dermatitis	Desonide cream 0.05%  Triamcinolone acetonide cream, lotion 0.025%  Betamethasone valerate 0.1% lotion  Fluocinolone acetonide 0.01% oil	Low/Class VI	Hands, feet, scalp, trunk, arms, legs, face, groin, periorbital
Moderate Atopic Dermatitis	Betamethasone valerate 0.1% cream  Triamcinolone acetonide ointment 0.025%, lotion 0.1%  Desonide ointment 0.05%  Fluticasone propionate cream 0.05%	Lower-mid/Class V	Hands, feet, scalp, trunk, arms, legs, face, groin
	Triamcinolone ointment, cream 0.1%  Mometasone furoate cream 0.1%	Medium/Class IV	
	Fluticasone propionate ointment 0.005%  Triamcinolone acetonide ointment 0.05%  Mometasone furoate ointment 0.1%	High/Class III	Hands, feet, scalp, trunk, arms, legs
Severe Atopic Dermatitis	Clobetasol propionate cream 0.025%  Fluocinonide cream, gel, ointment, solution 0.05%	High/Class II	Hands, feet, scalp, trunk, arms, legs
	Clobetasol propionate cream, ointment, gel 0.05%	Super-high/Class I, special consideration in peds for a limited time	Hands, feet

# **Steroid-Free Options**

### Steroid-free options work best for mild eczema and / or areas of thinner skin:

(Specialists may use this for areas of chronic eczema)

### **Topical Calcineurin Inhibitors**

- Not approved for kids under 2 years of age
- Great for face, groin, axilla which are thinner skin areas
- Tacrolimus 0.03% ointment children 2-15 years
- Tacrolimus 0.1% ointment children ≥ 16 years
- Pimecrolimus 1% cream children > 2 years of age

### Eucrisa (Crisaborole 2% ointment) consider in:

- Children older than 3 months
- Areas of skin involvement are thin (neck, face, groin, armpit)

**Algorithm** 

Treatment of Flares

### **Oral Steroids**

Oral steroids may be used in severe disease to facilitate more rapid improvement in symptoms while waiting for topical steroids to take effect.

### Indication:

Severe head-toe disease that is too extensive for adequate coverage by topical steroids

### **Considerations:**

- Address infectious etiologies or co-existing conditions contributing to severity
- Oral steroids should not be given more than once per year
- Treatment is tapered over 10 days:
  - 1 mg/kg (max 60 mg) Prednisolone Q day x 2 days
  - 0.8 mg/kg Prednisolone Q day x 2 days
  - 0.6 mg/kg Prednisolone Q day x 2 days
  - 0.4 mg/kg Prednisolone Q day x 2 days
  - 0.2 mg/kg Prednisolone Q day x 2 days

**Algorithm** 

Treatment of Flares

# Systemic Therapy

### **Systemic Therapy**

- **Dupixent**
- Methotrexate
- Cyclosporine
- Azathioprine
- Narrowband Ultraviolet Light Therapy

Vaccine administration and management of illness may be impacted while on systemic medications

Systemic medications should be managed by dermatology or allergy specialists.

Patients on these medication are selected based on severity, chronicity, quality of life, and coexistence of other atopic diseases (asthma, allergic rhinitis). The decision of which medication your patient is treated with can be based on response to treatment, insurance, contact allergen triggers, skin type, among others. Despite systemic medications, patients are encouraged to maintain topical skin care routine, avoidance of allergens, and may still require topical treatments or allergy shots.

**Algorithm** 

**Treatment of Flares** 

# **Adjuvant Therapy Options**

### Sedating, 1<sup>st</sup> Generation Antihistamine

- Consider as needed in children with disordered sleep
- Hydroxyzine:

Patient weight ≤40 kg: Oral: 2 mg/kg/day divided every 6 to 8 hours (max dose 25 mg/dose)

Patient weight >40 kg: Oral: 25 to 50 mg once daily at bedtime or twice daily

Children <6 years: Oral: 12.5 mg 3 to 4 times daily

Children ≥6 years and Adolescents: Oral: 12.5 to 25 mg 3 to 4 times daily

 Consider referral to allergy or dermatology if patient requiring frequent use of 1<sup>st</sup> generation antihistamines

### Non-sedating, 2<sup>nd</sup> Generation Antihistamines

- Consider in children with other symptoms of allergic rhinitis or urticaria
- Consider in children with constant pruritis (weak evidence)
  - o Cetirizine 2.5 mg daily as needed (children 6-23 months of age)

Or

2.5-5 mg daily as needed (children 2-6 years)

Or

5-10 mg daily as needed (children > 6 years)

### **Bleach Baths**

- Consider in children with frequent flares of super-infected atopic dermatitis
- Dilute bleach: Recipe: ¼ cup of bleach in ½ bath of water

**Algorithm** 

Treatment of Flares

### **Evaluate for Infections**

# Determination of infection is a clinical diagnosis May need to consider treatment for both viral and bacterial infections

### **Bacterial**

Impetigo bullous vs nonbullous, cellulitis, folliculitis, ecthyma Common causes: S. aureus, S. pyongenes

- Different characteristics will be observed depending on the location of the infection
- Findings include: cracking, honey crusting, excoriation, pustules, bullae, ulceration/erosions, induration/warmth
- Can be painful and may have associated pruritis

### Testing:

- Not recommended to swab atopic dermatitis patients for Gram stain/wound cultures routinely as there
  can be colonization
- Recurrent or severe flares with poor response to atomic dermatitis therapies may benefit from obtaining Gram stain/wound culture

Obtain Aerobic Wound Culture and Gram stain by swabbing over crust drainiage or pustules

### Viral

Eczema herpeticum, Herpes Simplex Virus 1

- HSV lesions are typically clustered, with vesicles, hemorrhagic crusting, most classically recognized by punched-out erosions.
  - HSV PCR
     Obtain by swabbing skin with cotton tip applicator and placing in viral culture medium.

#### Eczema coxsackium coxsackievirus

- Child may have fever, overall malaise and ill-appearance.
- Vesiculobullous lesions seen in Hand Foot Mouth disease, as well as the lesions seen in Eczema herpeticum, will concentrate in regions of atopic dermatitis that are currently or formerly flared.
  - Enterovirus PCR, if available and unable to clinically diagnose.
     Obtain by swabbing skin with cotton tip applicator and placing in viral culture medium.

### **Fungal**

Dermatophyte infections

- Annular (ring-shaped) plague with central clearing and raised border. May have coalescing plagues.
  - KOH prep

Malassezia furfur

- May be exacerbating factor in head and neck atopic dermatitis.
  - IgE specific to Malassezia

**Algorithm** 

Treatment of Infections

# **Treatment of Infections**

### **Bacterial**

Staphylococcus, Streptococcus

- o Small region, localized:
  - Apply Mupirocin ointment BID for 5 days (50% of staphylococcus patients resistant to Mupirocin)
- More extensive region:
  - Cephalexin 25-50mg/kg/day (max 500 mg/dose) divided every 8 hours for 7-10 days OR
  - Clindamycin PO 10mg/kg/dose (max 450 mg/dose) every 8 hours for 10 days
- Tailor treatment to pathogen identification and sensitivities.

#### Viral

Herpes Simplex Virus (HSV), Eczema Herpeticum

- Very mild, localized cases, child is well-appearing:
  - Acyclovir PO 20mg/kg/dose (max 800 mg/dose) 4 times daily for 7 days.
- More generalized skin involvement, child ill-appearing, recurrent infection, failed oral therapy, not tolerating liquids:
  - Acyclovir IV 5mg/kg/dose every 8 hours. Continue IV until lesions show regression, then may continue PO until resolution, 7-10 days.
- Consider maintenance therapy if more than 6 outbreaks in a year.

Enterovirus, Eczema Coxsackium

- No treatment necessary, unless considering HSV infection
  - In which case, may start acyclovir while awaiting available PCR results

### **Fungal**

Malassezia furfur

- o Selenium sulfide shampoo/lotion for 7 days or clotrimazole cream topical twice daily for 2-3 weeks.
  - If not controlled by topical treatment, consider referral to dermatology

# Co-Existing or Exacerbating Conditions & Treatment

### **Contact Dermatitis**

- Infants/Children with atopic dermatitis are more likely to develop contact dermatitis.
- Consider when children are not responding to routine treatment for atopic dermatitis or when spreads beyond typical distribution.
- Consider referral to dermatology
- Consider changing topical steroid (prefer desoximetasone 0.05% or 0.25% if contact dermatitis is suspected).
- Consider changing moisturizer (prefer Vani cream if contact dermatitis is suspected).
- Eliminate fragrances, detergents, irritants.

### **Seborrhea**

- Infants with scaly lesions in scalp and eyebrows.
- Application of emollient or non-medicated shampoo to soften scales and removal with soft brush (such as toothbrush).
- Topical steroids (topical 1% hydrocortisone).
- Selenium sulfide (Selsen Blue) shampoo 2% 2 times per week for 2-4 weeks.

# **Allergen Introduction**

#### Allergen Introduction

- Most children do not need testing or an allergy referral prior to the introduction of allergenic foods.
- Allergy testing is not indicated for children with atopic dermatitis unless they have had a reaction concerning for an IgE
  mediated allergy. An IgE mediated allergic reaction typically involves cutaneous, respiratory or GI symptoms that are rapid
  in onset and resolve within 1-2 hours. Typically these reactions are not limited to mild contact reactions around the mouth.
   IgE mediated allergic reactions do not cause chronic or delayed symptoms.
- False positive food allergy tests are frequent, so strongly consider referring to an allergy specialist in the event of a positive food allergy test for a formal food challenge.
- For all infants < 11 months, encourage early introduction of peanut and other allergenic foods including eggs, milk, tree nuts and wheat. This recommendation is essential for infants with moderate to severe eczema. It is also important to ensure infants with moderate to severe eczema maintain these allergenic foods in their diet.
- If patient's family is not comfortable with introduction, consider a referral to Early Peanut Introduction Clinic for further discussion.

### Instructions for first introducing peanuts for very young children/infants

- The developmental readiness of the infant must always be considered prior to introduction of any peanut containing foods and they should be eating other solid foods prior to introducing peanut.
- Whole or divided peanuts should never be given to an infant due to risk for choking.

### There are several sources that can be used to offer 2 grams of peanut protein per feeding

- Thinned smooth peanut butter:
  - Measure 2 teaspoons of peanut butter and slowly add 2-3 teaspoons of hot water
  - Stir until dissolved and well blended
  - Let cool
  - Increase water amount if necessary or add to previously tolerated infant cereal to achieve consistency comfortable for the infant
- Smooth peanut butter puree:
  - Measure 2 teaspoons of peanut butter
  - Add 2-3 tablespoons of pureed tolerated fruit or vegetables to peanut butter
  - Volume of puree can be adjusted to achieve desired consistency
- Peanut flour and peanut butter powder:
  - Measure 1 teaspoon of either product (both interchangeable)
  - Add 2 tablespoons of pureed tolerated fruits or vegetables to flour or powder
  - Volume of puree can be adjusted to achieve desired consistency
- Peanut-containing puffs or sticks:
  - 21 sticks = ~2 g of peanut protein
  - Infants < 7 months of age: soften with 4-6 teaspoons of water</li>
  - Older infants can eat unmodified but can also soften, if desired

# **Subspecialty Referral**

### Referral to allergy

- Known or suspected food allergy
- o Families with questions or hesitation about early allergen introduction
- Infants with severe atopic dermatitis
- Atopic dermatitis coexistent with moderate to severe asthma
- Environmental triggers suspected (eyelid eczema)
- Strong family history of atopy in older children with developing symptoms
- o Referrals are not indicated solely because there is a sibling or family history of food allergy

### Referral to dermatology

Moderate or severe atopic dermatitis

High body surface area

Multiple body surface areas resulting in multiple different strengths of topical steroids

Failing to respond to routine therapy over 1-2 months

Frequent secondary infections

History of requiring oral steroids more than once per year

Affecting quality of life

<u>Differential</u> <u>Diagnosis</u>

- Questionable or unclear diagnosis
- Suspicions for contact dermatitis
- Need for additional treatment (systemic medication including biologics)

### Referral to immunology

- o Severe atopic dermatitis in a young infant with other concerning symptoms
- Frequent or unusual infections
- o Poor weight gain or diarrhea in an infant
- Unusual distribution of atopic dermatitis (for example, in the diaper area)

### **Infants Under 2 Months**

- Aggressive use of emollient to improve skin barrier is recommended.
- Treatment with topical steroids (hydrocortisone 1% for infants under 1 month, hydrocortisone 2.5% for infants 1-2 months).
- Consider treatment of <u>seborrhea</u> when there is extensive forehead, central facial and chest dermatitis.
- Consider differential diagnosis and refer to dermatology.
- Consider referral to immunology if atopic dermatitis is severe, especially if baby has other GI symptoms such as poor weight gain or diarrhea.

### References

- 1. Rangerl SM, Paller AS. Bacterial colonization, overgrowth, and superinfection in atopic dermatitis. *Clin Dermatol.* 2018;35(5):641-647.
- 2. Mooney E, et al. Adverse effects of topical corticosteroids in paediatric eczema: Australian consensus statement. *Aust J Dermatol.* 2015;56(4):241-251.
- 3. Togias A, Cooper SF, Acebal ML, et al. Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. *J Allergy Clin Immunol.* 2017;139(1):29-44.
- 4. ASCIA. ASCIA guide for introduction of peanut to infants with severe eczema and/or food allergy. Available from: www.allergy.org.au.
- 5. Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. *N Engl J Med*. 2015;372(9):803-813.
- 6. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: Section 3. *J Am Acad Dermatol*. 2014;71:327-349.
- 7. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. *J Allergy Clin Immunol*. 2013;131(2):295-299.e1-27.
- 8. National Institute for Health Care and Excellence (NICE). Atopic eczema in under 12s: diagnosis and management. *NICE Clinical Guidelines*, No. 57. March 2021.

### **Team & Process**

### **Content Development Team:**

Leaders:

Allergy/Immunology:

Irene Mikhail, MD

Dermatology:

Joy Mosser-Goldfarb, MD

**Emergency Medicine:** 

Berkeley Bennett, MD, MS

**Members:** 

**Emergency Medicine:** 

Laura Rust, MD, MPH Joelle Farlow, DO Anita Yalamanchi, DO

Nkeiruka Orajiaka MD, MPH, FAAP

Primary Care Pediatrics:

Milagro Castaneda, MD Meghan Dishong, MD Ranee Jostpille, MD

Pharmacy:

Kimberly Jones, PharmD

Allergy/Immunology:

Christian Coletta, MD

**Clinical Pathways Program:** 

Medical Director – Emergency Medicine:

Berkeley Bennett, MD, MS

Medical Director – Clinical Informatics & Emergency Medicine:

Laura Rust, MD, MPH

Physician Informatics:

Kathy Nuss, MD

Business & Development Manager:

Rekha Voruganti, MBOE, LSSBB

Program Coordinators:

Tahje Brown, MBA Tara Dinh, BS

**Clinical Pathway Approved:** 

Medical Director - Associate Chief Quality Officer, Center for

Clinical Excellence:

Ryan Bode, MD, MBOE

Origination Date: January, 2023

Next Revision Date: January, 2026

### **Clinical Pathway Development**

This clinical pathway was developed using the process described in the NCH Clinical Pathway Development Manual Version 6, 2022. Clinical Pathways at Nationwide Children's Hospital (NCH) are standards which provide general guidance to clinicians. Patient choice, clinician judgment, and other relevant factors in diagnosing and treating patients remain central to the selection of diagnostic tests and therapy. The ordering provider assumes all risks associates with care decisions. NCH assumes no responsibility for any adverse consequences, errors, or omissions that may arise from the use or reliance on these guidelines. NCH's clinical pathways are reviewed periodically for consistency with new evidence; however, new developments may not be represented, and NCH makes no guarantees, representations, or warranties with respect to the information provided in this clinical pathway.

Copyright © 2023. Nationwide Children's Hospital. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any form without the express written permission of Nationwide Children's Hospital.

For more information about our pathways and program please contact: ClinicalPathways@NationwideChildrens.org

# Atopic Dermatitis: Appropriate Steroid Class for Anatomic Location

